FDA staff cautious on AstraZeneca, Bristol diabetes drug
LONDON Dec 10 (Reuters) - U.S. Food and Drug Administration staff said on Tuesday they were wary about the benefits versus the risks of AstraZeneca and Bristol-Myers Squibb's new diabetes drug dapagliflozin in documents posted on the agency's website.
It was not possible to conclude with confidence that the purported cardiovascular benefit associated with using the drug outweighed "the observed imbalance in specific malignancies or potential liver toxicity risks", they said.
The briefing documents were posted ahead of an advisory committee meeting on Thursday.
- Malaysia military tracked missing plane to west coast: source |
- Malaysia air probe finds scant evidence of attack: sources |
- Ukraine forms new defense force, seeks Western help |
- UPDATE 1-Missing Malaysian plane last seen at Strait of Malacca-source
- Freescale loss in Malaysia tragedy leads to travel policy questions